方法：对19例20眼因眼外伤行穿透性角膜移植术后3mo，新生血管增生达到Ⅲ度以上患眼随机分为四组。A组：对照组； B组：贝伐单抗2.5mg(0.1mL)； C组：贝伐单抗及曲安奈德各0.1mL； D组：曲安奈德0.1mL； 每月1次，共两次球结膜下注射药物。

结果：平均随访3a，B组和C组视力保持稳定或稍有增进，新生血管和免疫反应明显减退(P<0.01)，患者眼痛、畏光流泪症状减轻。

结论：贝伐单抗联合曲安奈德在治疗穿透性角膜移植术后新生血管的过程中能够有效减退新生血管，并减轻排斥反应，对保持植片的透明性有积极的治疗作用。

METHODS: Nineteen patients(20 eyes)with CNV induced by penetrating keratoplasty after 3mo were selected and were divided into 4 groups randomly: Group A was control group, group B was treated by subconjunctival of bevacizumab(2.5mg, 0.1mL), group C was treated by subconjunctival of bevacizumab(2.5mg, 0.1mL)and TA(4mg, 0.1mL), group D was treated by subconjunctival of TA(4mg, 0.1mL), one time each month, twice.

RESULTS: The average follow-up period was 3a. Visual acuity of groups B and C kept stable or increase slightly. CNV and immunologic rejection were lighten(P<0.01), symptomatic of ophthalmalgia and photophobia relief synchronous.

CONCLUSION: Treatment of subconjunctival bevacizumab and TA can effectively inhibite CNV and immunologic rejection, also has the therapeutical effect to maintain implant transparence after penetrating keratoplasty.